Clinical Trial Update: A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma [Phase 3]

View source ↗

Summary

This is a Phase 3 clinical trial evaluating ficlatuzumab plus cetuximab in patients with recurrent or metastatic HPV-negative head and neck squamous cell carcin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• ERBITUX (cetuximab)
• Ficlatuzumab (ficlatuzumab)

Snippet

Sponsor: AVEO Pharmaceuticals, Inc. | Conditions: Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 3 | Status: RECRUITING